stockrowGilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.3%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
Follow GILD
Alert me
Gilead Sciences, Inc. (GILD) Return on equity
Gilead Sciences, Inc.'s return on equity over the twelve months to 30 September 2026 was −22.5%, down 63.1 percentage points from fiscal 2025 (40.7%). Over the past ten years it has ranged from 0.60% (fiscal 2020) to 103.7% (fiscal 2015); the current reading is higher than 82% of that period. That is below the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 40.7% | 38.37 |
| FY2024 | 2.29% | (23.48) |
| FY2023 | 25.8% | 4.04 |
| FY2022 | 21.7% | (9.96) |
| FY2021 | 31.7% | 31.09 |
| FY2020 | 0.60% | (23.78) |
| FY2019 | 24.4% | (1.57) |
| FY2018 | 26.0% | 2.73 |
| FY2017 | 23.2% | (46.96) |
| FY2016 | 70.2% | (33.50) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 78.4% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company compare | 44.0% |
| NVS Novartis AG compare | 24.4% |
| AZN AstraZeneca PLC compare | 22.6% |
| PFE Pfizer Inc. compare | 4.42% |
| SNY Sanofi compare | 0.00% |
| MRK Merck & Co., Inc. compare | 0.00% |
| GILD Gilead Sciences, Inc. | −22.5% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement